Xponance Inc. Grows Stake in Vaxcyte, Inc. (NASDAQ:PCVX)

Xponance Inc. increased its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 13.4% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 8,905 shares of the company’s stock after acquiring an additional 1,052 shares during the quarter. Xponance Inc.’s holdings in Vaxcyte were worth $729,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Whipplewood Advisors LLC bought a new position in Vaxcyte in the 4th quarter worth about $28,000. Smartleaf Asset Management LLC increased its position in shares of Vaxcyte by 188.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock worth $33,000 after purchasing an additional 260 shares during the last quarter. Blue Trust Inc. raised its stake in Vaxcyte by 100.0% in the fourth quarter. Blue Trust Inc. now owns 742 shares of the company’s stock valued at $61,000 after purchasing an additional 371 shares in the last quarter. Assetmark Inc. lifted its position in Vaxcyte by 77,500.0% during the fourth quarter. Assetmark Inc. now owns 776 shares of the company’s stock valued at $64,000 after purchasing an additional 775 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. purchased a new position in Vaxcyte in the 3rd quarter worth approximately $92,000. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Trading Down 1.1 %

PCVX opened at $73.82 on Tuesday. Vaxcyte, Inc. has a 12 month low of $58.10 and a 12 month high of $121.06. The business’s 50-day moving average price is $81.26 and its 200-day moving average price is $93.61. The company has a market cap of $9.51 billion, a P/E ratio of -16.05 and a beta of 1.02.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.14. Equities research analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Insider Activity at Vaxcyte

In related news, CFO Andrew Guggenhime sold 8,000 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $86.51, for a total value of $692,080.00. Following the sale, the chief financial officer now directly owns 109,491 shares of the company’s stock, valued at $9,472,066.41. This trade represents a 6.81 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Teri Loxam sold 6,250 shares of the business’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total value of $531,937.50. Following the transaction, the director now owns 7,175 shares in the company, valued at approximately $610,664.25. This represents a 46.55 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 46,250 shares of company stock worth $3,840,018 in the last three months. 3.10% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Guggenheim reaffirmed a “buy” rating and set a $160.00 price objective on shares of Vaxcyte in a report on Wednesday, March 12th. Needham & Company LLC reaffirmed a “buy” rating and set a $140.00 price target on shares of Vaxcyte in a research note on Wednesday, February 26th. Finally, The Goldman Sachs Group started coverage on Vaxcyte in a research report on Friday, December 20th. They set a “buy” rating and a $135.00 price objective on the stock. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat, Vaxcyte has a consensus rating of “Buy” and an average target price of $147.50.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.